Krishna Institute of Medical Sciences Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, demonstrating strong operational performance and strategic expansion initiatives. The healthcare services provider reported significant revenue growth while maintaining its focus on expanding its presence in the medical sector.

Consolidated Financial Performance

The company delivered robust consolidated financial results for Q3FY26, with revenue from operations showing substantial growth compared to the previous year.

For the nine-month period ended December 31, 2025, the company maintained strong momentum with consolidated revenue from operations reaching Rs 28,300 million compared to Rs 22,381 million in the corresponding period of the previous year, marking a growth of 26.43%.

Standalone Results Show Consistent Growth

The standalone financial performance also reflected positive trends, with the parent company showing healthy operational metrics.

The standalone revenue growth of 27.17% in Q3FY26 demonstrates the core business strength, while the nine-month standalone revenue reached Rs 12,453 million compared to Rs 10,382 million in the previous year.

Strategic Investment in Material Subsidiary

The Board of Directors approved a significant strategic initiative involving increased investment in Sarvejana Healthcare Private Limited, the company's material subsidiary operating Sunshine Hospital.

Sunshine Hospital, incorporated on December 3, 2008, operates as a specialized orthopedic hospital with joint replacement as its core service, supplemented by other high-end healthcare facilities including cardiology and transplant services. The hospital has shown consistent growth with turnover increasing from Rs 419.44 crores in FY23 to Rs 597.00 crores in FY25.

Operational Highlights and Business Segment

Krishna Institute of Medical Sciences operates in a single reportable business segment of "Medical and Healthcare services." The company's expense management showed disciplined growth, with total consolidated expenses increasing to Rs 9,343 million in Q3FY26 from Rs 6,556 million in Q3FY25.

The company's financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 6, 2026. The statutory auditors S.R. Batliboi & Co. LLP expressed an unmodified opinion on both consolidated and standalone financial results, confirming the accuracy and compliance of the financial statements with applicable accounting standards.

Krishna Institute of Medical Sciences Limited has announced the successful completion of its postal ballot process, with shareholders overwhelmingly approving a material related party transaction with its subsidiary company. The voting concluded on February 01, 2026, marking a significant milestone in the company's corporate governance processes.

Voting Results and Participation

The postal ballot witnessed strong shareholder participation, with detailed voting statistics reflecting broad-based support for the proposed resolution.

Resolution Details and Approval

The single ordinary resolution on the agenda concerned the approval of a material related party transaction with KIMS Hospital Bengaluru Private Limited, a subsidiary company. The voting results demonstrated overwhelming shareholder support across all categories.

Voting Breakdown by Category

Scrutinizer's Oversight and Process

Krishna Rao Inturi, Proprietor of IKR & Associates and Practicing Company Secretary, served as the appointed scrutinizer for the postal ballot process. The scrutinizer was appointed by the board of directors through a resolution passed on December 29, 2025, ensuring independent oversight of the voting process.

The e-voting facility was provided by MUFG Intime India Private Limited, with the platform remaining accessible from January 03, 2026, 09:00 AM to February 01, 2026, 05:00 PM. The votes were unblocked on February 02, 2026, in the presence of two independent witnesses who were not employed by the company.

Regulatory Compliance and Documentation

The postal ballot process was conducted in strict accordance with:

• Sections 108 and 110 of the Companies Act, 2013
• Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014
• Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The voting results and scrutinizer's report have been disclosed to both BSE and NSE, with the company maintaining transparency through uploads on its website www.kimshospitals.com and the e-voting platform. The resolution is deemed to have been passed on February 01, 2026, the last date of e-voting, with the requisite majority achieved as confirmed by the scrutinizer's report dated February 03, 2026.